CN102388307B - 多发性硬化的诊断 - Google Patents

多发性硬化的诊断 Download PDF

Info

Publication number
CN102388307B
CN102388307B CN200980154256.5A CN200980154256A CN102388307B CN 102388307 B CN102388307 B CN 102388307B CN 200980154256 A CN200980154256 A CN 200980154256A CN 102388307 B CN102388307 B CN 102388307B
Authority
CN
China
Prior art keywords
antigens
antigen
reactivity
listing
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980154256.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102388307A (zh
Inventor
霍华德·L·韦纳
艾润·R·科恩
弗朗西斯科·J·昆塔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Brigham and Womens Hospital Inc
Original Assignee
Yeda Research and Development Co Ltd
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Brigham and Womens Hospital Inc filed Critical Yeda Research and Development Co Ltd
Publication of CN102388307A publication Critical patent/CN102388307A/zh
Application granted granted Critical
Publication of CN102388307B publication Critical patent/CN102388307B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200980154256.5A 2008-11-12 2009-11-12 多发性硬化的诊断 Expired - Fee Related CN102388307B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11364508P 2008-11-12 2008-11-12
US61/113,645 2008-11-12
PCT/IL2009/001066 WO2010055510A2 (en) 2008-11-12 2009-11-12 Diagnosis of multiple sclerosis

Publications (2)

Publication Number Publication Date
CN102388307A CN102388307A (zh) 2012-03-21
CN102388307B true CN102388307B (zh) 2014-09-03

Family

ID=42170484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980154256.5A Expired - Fee Related CN102388307B (zh) 2008-11-12 2009-11-12 多发性硬化的诊断

Country Status (7)

Country Link
US (1) US9267945B2 (enExample)
EP (1) EP2353004B1 (enExample)
JP (1) JP2012508865A (enExample)
CN (1) CN102388307B (enExample)
AU (1) AU2009315230A1 (enExample)
CA (1) CA2743590A1 (enExample)
WO (1) WO2010055510A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105980A1 (en) 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US8652999B1 (en) 2012-07-24 2014-02-18 Dow Agrosciences, Llc. Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and a sulfonylaminocarbonyltriazolinone
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
PT3065771T (pt) 2013-11-04 2019-06-24 Uti Lp Metodos e composicoes para imunoterapia prolongada
CA2933554A1 (en) * 2013-12-12 2015-06-18 The Brigham And Women's Hospital, Inc. Treating neurodegenerative disease
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
US20160320384A1 (en) 2013-12-31 2016-11-03 Yeda Research And Development Co. Ltd. Methods for assaying immunological competence
EP3123176A4 (en) * 2014-03-23 2018-04-25 The Regents of the University of Colorado Diagnosis of multiple sclerosis in human and animal subjects
EP2927687A1 (en) * 2014-03-31 2015-10-07 Ecole Polytechnique Federale de Lausanne (EPFL) Agents useful in diagnostic and therapy of beta-amyloid aggregation related disorders and screening methods
WO2015172008A1 (en) * 2014-05-09 2015-11-12 Multiple Sclerosis Research Center Of New York Transglutaminadase 6 as a biomarker for multiple sclerosis
US10495646B2 (en) 2015-01-30 2019-12-03 The Regents Of The University Of California N-acetyl glucosamine as a biomarker of MS disease course
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN107043413A (zh) * 2016-02-05 2017-08-15 华中农业大学 一种肺结核相关的尿液生物标志蛋白及其应用
US11402379B2 (en) * 2016-09-09 2022-08-02 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune GFAP astrocytopathy
EP3538559B1 (en) 2016-11-09 2025-04-09 UTI Limited Partnership Recombinant pmhc class ii molecules
KR20200004807A (ko) 2017-04-07 2020-01-14 유티아이 리미티드 파트너쉽 나노의약에서 수용체-리간드 상호작용의 효능을 측정하기 위한 어세이
AU2018374569B2 (en) 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2021212013A2 (en) 2020-04-17 2021-10-21 Op-T Llc Bioactive peptides and methods of use thereof
CN114689865A (zh) * 2020-12-30 2022-07-01 广州市微米生物科技有限公司 视神经脊髓炎抗体检测试剂
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529617A (zh) * 2001-01-09 2004-09-15 ��������ͨ���о�Ժ 受试者的自身免疫疾病的治疗方法及其体外诊断测定
WO2006077126A2 (en) * 2005-01-19 2006-07-27 Bayer Schering Pharma Aktiengesellschaft Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients
WO2007056332A2 (en) * 2005-11-07 2007-05-18 Vanderbilt University Molecular diagnosis of autoimmune diseases
CN101010098A (zh) * 2004-07-01 2007-08-01 哥本哈根大学 通过对钩端螺旋体感染的治疗进行多发性硬化症治疗和预防的方法
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
JP4594588B2 (ja) 2001-04-10 2010-12-08 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ 抗体特異的プロファイルの治療的および診断的使用方法
US20030092089A1 (en) 2001-11-14 2003-05-15 Moscarello Mario Anthony Method for diagnosing multiple sclerosis and an assay therefore
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
US20050009096A1 (en) 2002-10-11 2005-01-13 The Regents Of The University Of California Method for diagnosis and prognosis of multiple sclerosis
US20050260770A1 (en) 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US7572592B2 (en) * 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
WO2006116155A2 (en) * 2005-04-21 2006-11-02 The Regents Of The University Of California A method for diagnosis and prognosis of multiple sclerosis subtypes
US8252775B2 (en) * 2005-07-21 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Method of treating multiple sclerosis with phosphocholine containing lipids
CN101479230A (zh) * 2006-05-26 2009-07-08 菲诺梅诺米发现公司 用于诊断多发性硬化的生物标记及其方法
CA2683865A1 (en) 2007-04-12 2008-10-23 Apitope International Nv Biomarkers for multiple sclerosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529617A (zh) * 2001-01-09 2004-09-15 ��������ͨ���о�Ժ 受试者的自身免疫疾病的治疗方法及其体外诊断测定
CN101010098A (zh) * 2004-07-01 2007-08-01 哥本哈根大学 通过对钩端螺旋体感染的治疗进行多发性硬化症治疗和预防的方法
WO2006077126A2 (en) * 2005-01-19 2006-07-27 Bayer Schering Pharma Aktiengesellschaft Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
WO2007056332A2 (en) * 2005-11-07 2007-05-18 Vanderbilt University Molecular diagnosis of autoimmune diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The immunopathology of multiple sclerosis: an overview.;Lassmann H, Brück W, Lucchinetti CF.;《Brain Pathol》;20070430;第17卷(第2期);210-218 *
多发性硬化患者合并症的临床介析;吕继辉等;《中国临床医生杂志》;20071231;第35卷(第10期);28-29 *

Also Published As

Publication number Publication date
WO2010055510A2 (en) 2010-05-20
EP2353004A4 (en) 2012-04-18
CA2743590A1 (en) 2010-05-20
CN102388307A (zh) 2012-03-21
EP2353004A2 (en) 2011-08-10
AU2009315230A1 (en) 2010-05-20
US20120077686A1 (en) 2012-03-29
JP2012508865A (ja) 2012-04-12
US9267945B2 (en) 2016-02-23
HK1168423A1 (en) 2012-12-28
WO2010055510A3 (en) 2010-09-16
EP2353004B1 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
CN102388307B (zh) 多发性硬化的诊断
US12560619B2 (en) Methods and compositions for diagnosing brain injury or neurodegeneration
JP4659025B2 (ja) 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
Mike et al. Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus
Akman-Demir et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients
US20140303041A1 (en) In vitro diagnostic devices for nervous system injury and other neural disorders
Zoltewicz et al. Characterization of antibodies that detect human GFAP after traumatic brain injury
CN107621545B (zh) Bicc1蛋白对精神疾病诊断的新用途
US20240302359A1 (en) Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
JPWO2018221212A1 (ja) アルツハイマー病バイオマーカー
Siman et al. Serum SNTF, a surrogate marker of axonal injury, is prognostic for lasting brain dysfunction in mild TBI treated in the emergency department
Virhammar et al. Biomarkers for CNS injury in CSF are elevated in COVID-19 and associated with neurological symptoms and disease severity
US11619632B2 (en) Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
CA3163308A1 (en) Kinases as biomarkers for neurodegenerative conditions
HK1168423B (en) Diagnosis of multiple sclerosis
Shimo et al. Social stress induces autoimmune responses against the brain to promote stress susceptibility
JP2021060289A (ja) 細胞内コレステロールレベルに関連する疾患の、診断用マーカー、診断を補助する方法、診断のためにデータを収集する方法、罹患可能性を評価する方法、及び診断用キット
US20260002947A1 (en) Methods, systems and compositions for traumatic brain injury and associated neurodegenerative disease immune response diagnostics
JP2007183176A (ja) 重症筋無力症の診断方法およびそのキット
US20220236290A1 (en) Methods, systems and compositions for traumatic brain injury and associated neurodegenerative disease immune response diagnostics
US20220276264A1 (en) DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES
Polidoro et al. Spinal fluid antibody profile against bacteria demonstrates intrathecal antibody production in demyelinating diseases
Kruszewska et al. Agnieszka Kulczyńska-Przybik1✉, Piotr Czupryna2, Justyna Adamczuk2
RU2531922C2 (ru) Способ молекулярной диагностики состояния психосоматических функций у пациентов с дисциркуляторной энцефалопатией
Nováková Nyrén Biomarkers in Multiple Sclerosis-Monitoring disease activity and treatment afficacy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168423

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1168423

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140903

Termination date: 20181112

CF01 Termination of patent right due to non-payment of annual fee